GLP1R and metabolic dysfunction-associated steatotic liver disease: Furthermore, the European Association for the Study of the Liver (EASL) recommends emphasizing the potential advantages of GLP-1-RAs in treating non-alcoholic fatty liver disease (NAFLD), particularly in patients with T2DM [101].